As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
Commentary|Articles|December 28, 2025
Interview with Sa'ed al-Olimat, PharmD: How Pharmacists are Shaping the Future of Psychedelic Therapy
Author(s)Sa'ed Al-Olimat, PharmD
Fact checked by: Laura Silvius, Managing Editor
Pharmacists must adapt to the evolving landscape of psychedelic therapies, focusing on education, patient support, and understanding regulatory challenges.
Advertisement
Advertisement
As psychedelic therapies continue to gain ground in the popular zeitgeist and edge closer to clinical use, pharmacists need to develop new competencies beyond traditional medication management. In an exclusive interview with Pharmacy Times, Sa'ed al-Olimat, PharmD, thinks the FDA's recent decision on 3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy highlights why pharmacists must be educators in this rapidly evolving therapeutic space.
Related to this article
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement